{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T13:45:47Z","timestamp":1758807947719,"version":"3.44.0"},"reference-count":81,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Clinics of North America"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1016\/j.ucl.2013.01.008","type":"journal-article","created":{"date-parts":[[2013,3,5]],"date-time":"2013-03-05T20:02:39Z","timestamp":1362513759000},"page":"219-232","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["New Agents for Bacillus Calmette-Gu\u00e9rin\u2013Refractory Bladder Cancer"],"prefix":"10.1016","volume":"40","author":[{"given":"Jennifer J.","family":"Ahn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James M.","family":"McKiernan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2012","series-title":"SEER cancer statistics review, 1975-2009 (Vintage 2009 Populations)","key":"10.1016\/j.ucl.2013.01.008_bib1"},{"issue":"2","key":"10.1016\/j.ucl.2013.01.008_bib2","first-page":"283","article-title":"Natural history and treatment of low and high risk superficial bladder tumors","volume":"139","author":"Rubben","year":"1988","journal-title":"J\u00a0Urol"},{"issue":"3 Pt 1","key":"10.1016\/j.ucl.2013.01.008_bib3","first-page":"680","article-title":"Primary superficial bladder cancer risk groups according to progression, mortality and recurrence","volume":"164","author":"Millan-Rodriguez","year":"2000","journal-title":"J\u00a0Urol"},{"issue":"1","key":"10.1016\/j.ucl.2013.01.008_bib4","first-page":"31","article-title":"Superficial bladder cancer: an update on etiology, molecular development, classification, and natural history","volume":"10","author":"Pasin","year":"2008","journal-title":"Rev Urol"},{"issue":"4","key":"10.1016\/j.ucl.2013.01.008_bib5","first-page":"377","article-title":"Bacillus Calmette-Guerin in the treatment of adenocarcinoma of the kidney","volume":"115","author":"Morales","year":"1976","journal-title":"J\u00a0Urol"},{"issue":"6","key":"10.1016\/j.ucl.2013.01.008_bib6","first-page":"2158","article-title":"A\u00a0review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group","volume":"186","author":"Brausi","year":"2011","journal-title":"J\u00a0Urol"},{"issue":"5","key":"10.1016\/j.ucl.2013.01.008_bib7","first-page":"1964","article-title":"Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials","volume":"168","author":"Sylvester","year":"2002","journal-title":"J\u00a0Urol"},{"issue":"3","key":"10.1016\/j.ucl.2013.01.008_bib8","first-page":"457","article-title":"Long-term results and complications of intracavitary bacillus Calmette-Guerin therapy for bladder cancer","volume":"132","author":"Morales","year":"1984","journal-title":"J\u00a0Urol"},{"issue":"2","key":"10.1016\/j.ucl.2013.01.008_bib9","first-page":"220","article-title":"Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer","volume":"137","author":"Catalona","year":"1987","journal-title":"J\u00a0Urol"},{"issue":"5","key":"10.1016\/j.ucl.2013.01.008_bib10","first-page":"1706","article-title":"Defining bacillus Calmette-Guerin refractory superficial bladder tumors","volume":"169","author":"Herr","year":"2003","journal-title":"J\u00a0Urol"},{"issue":"6 Suppl 1","key":"10.1016\/j.ucl.2013.01.008_bib11","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.urology.2005.08.066","article-title":"Management of stage T1 tumors of the bladder: international consensus panel","volume":"66","author":"Nieder","year":"2005","journal-title":"Urology"},{"issue":"1","key":"10.1016\/j.ucl.2013.01.008_bib12","first-page":"74","article-title":"The value of a second transurethral resection in evaluating patients with bladder tumors","volume":"162","author":"Herr","year":"1999","journal-title":"J\u00a0Urol"},{"issue":"6 Pt B","key":"10.1016\/j.ucl.2013.01.008_bib13","first-page":"E216","article-title":"Prognostic significance of bacillus Calmette-Guerin failure classification in non-muscle-invasive bladder cancer","volume":"110","author":"Shirakawa","year":"2012","journal-title":"BJU Int"},{"issue":"5","key":"10.1016\/j.ucl.2013.01.008_bib14","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S0090-4295(99)00591-9","article-title":"Long-term results of intravesical bacillus Calmette-Guerin therapy for stage T1 superficial bladder cancer","volume":"55","author":"Brake","year":"2000","journal-title":"Urology"},{"issue":"4","key":"10.1016\/j.ucl.2013.01.008_bib15","first-page":"1124","article-title":"Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study","volume":"163","author":"Lamm","year":"2000","journal-title":"J\u00a0Urol"},{"issue":"5","key":"10.1016\/j.ucl.2013.01.008_bib16","first-page":"1727","article-title":"Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer","volume":"177","author":"Lerner","year":"2007","journal-title":"J\u00a0Urol"},{"issue":"6","key":"10.1016\/j.ucl.2013.01.008_bib17","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.urology.2009.05.092","article-title":"Pathological upstaging during radical cystectomy is associated with worse recurrence-free survival in patients with bacillus Calmette-Guerin-refractory bladder cancer","volume":"74","author":"Guzzo","year":"2009","journal-title":"Urology"},{"issue":"1","key":"10.1016\/j.ucl.2013.01.008_bib18","first-page":"78","article-title":"Effect of preoperative delay on survival in patients with bladder cancer undergoing cystectomy in Quebec: a population based study","volume":"175","author":"Mahmud","year":"2006","journal-title":"J\u00a0Urol"},{"issue":"4 Pt 1","key":"10.1016\/j.ucl.2013.01.008_bib19","first-page":"1085","article-title":"Delaying radical cystectomy for muscle invasive bladder cancer results in worse pathological stage","volume":"170","author":"Chang","year":"2003","journal-title":"J\u00a0Urol"},{"issue":"4","key":"10.1016\/j.ucl.2013.01.008_bib20","first-page":"1318","article-title":"Longer wait times increase overall mortality in patients with bladder cancer","volume":"182","author":"Kulkarni","year":"2009","journal-title":"J\u00a0Urol"},{"issue":"4","key":"10.1016\/j.ucl.2013.01.008_bib21","first-page":"1296","article-title":"Does early cystectomy improve the survival of patients with high risk superficial bladder tumors?","volume":"166","author":"Herr","year":"2001","journal-title":"J\u00a0Urol"},{"issue":"4","key":"10.1016\/j.ucl.2013.01.008_bib22","first-page":"1283","article-title":"Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer","volume":"177","author":"Raj","year":"2007","journal-title":"J\u00a0Urol"},{"issue":"10","key":"10.1016\/j.ucl.2013.01.008_bib23","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1111\/j.1464-410X.2012.11116.x","article-title":"Immediate radical cystectomy vs conservative management for high grade cT1 bladder cancer: is there a survival difference?","volume":"110","author":"Badalato","year":"2012","journal-title":"BJU Int"},{"issue":"6","key":"10.1016\/j.ucl.2013.01.008_bib24","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.eururo.2011.03.017","article-title":"EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update","volume":"59","author":"Babjuk","year":"2011","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.ucl.2013.01.008_bib25","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0090-4295(99)00463-X","article-title":"Intravesical therapy for bladder cancer","volume":"55","author":"Kamat","year":"2000","journal-title":"Urology"},{"issue":"4","key":"10.1016\/j.ucl.2013.01.008_bib26","first-page":"1124","article-title":"5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group","volume":"161","author":"Malmstrom","year":"1999","journal-title":"J\u00a0Urol"},{"issue":"3","key":"10.1016\/j.ucl.2013.01.008_bib27","first-page":"777","article-title":"Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study","volume":"170","author":"Di Stasi","year":"2003","journal-title":"J\u00a0Urol"},{"issue":"23","key":"10.1016\/j.ucl.2013.01.008_bib28","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1200\/JCO.2003.01.089","article-title":"Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma","volume":"21","author":"Colombo","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"issue":"3 Pt 2","key":"10.1016\/j.ucl.2013.01.008_bib29","first-page":"959","article-title":"A\u00a0new approach using local combined microwave hyperthermia and chemotherapy in superficial transitional bladder carcinoma treatment","volume":"153","author":"Colombo","year":"1995","journal-title":"J\u00a0Urol"},{"issue":"4","key":"10.1016\/j.ucl.2013.01.008_bib30","first-page":"1375","article-title":"Effect of hyperthermia on the cytotoxicity of 4 chemotherapeutic agents currently used for the treatment of transitional cell carcinoma of the bladder: an in\u00a0vitro study","volume":"173","author":"van der Heijden","year":"2005","journal-title":"J\u00a0Urol"},{"issue":"3","key":"10.1016\/j.ucl.2013.01.008_bib31","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1046\/j.0306-5251.2001.01449.x","article-title":"Effect of local hyperthermia of the bladder on mitomycin C pharmacokinetics during intravesical chemotherapy for the treatment of superficial transitional cell carcinoma","volume":"52","author":"Paroni","year":"2001","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.ucl.2013.01.008_bib32","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s00345-009-0384-2","article-title":"Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: experience of the European Synergo working party","volume":"27","author":"Alfred Witjes","year":"2009","journal-title":"World J Urol"},{"issue":"4","key":"10.1016\/j.ucl.2013.01.008_bib33","first-page":"1313","article-title":"Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette-Guerin","volume":"182","author":"Nativ","year":"2009","journal-title":"J\u00a0Urol"},{"issue":"8","key":"10.1016\/j.ucl.2013.01.008_bib34","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1093\/jnci\/93.8.597","article-title":"Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial","volume":"93","author":"Au","year":"2001","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.ucl.2013.01.008_bib35","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s00345-009-0389-x","article-title":"Updates in intravesical electromotive drug administration of mitomycin-C for non-muscle invasive bladder cancer","volume":"27","author":"Di Stasi","year":"2009","journal-title":"World J Urol"},{"issue":"3","key":"10.1016\/j.ucl.2013.01.008_bib36","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S1569-9056(08)60435-2","article-title":"Carcinoma in situ of the bladder: long-term results of a randomized prospective study comparing intravesical electromotive mitomycin-C, passive diffusion mitomycin-C and Bacillus Calmette-Guerin","volume":"7","author":"Di Stasi","year":"2008","journal-title":"Eur Urol Suppl"},{"issue":"Suppl 5","key":"10.1016\/j.ucl.2013.01.008_bib37","first-page":"50","article-title":"Electro-motive drug administration (EMDA) of intravesical mitomycin-C in patients with high-risk non-invasive bladder cancer and failure of BCG immunotherapy","volume":"101","author":"Sockett","year":"2008","journal-title":"BJU Int"},{"issue":"1","key":"10.1016\/j.ucl.2013.01.008_bib38","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(05)70472-1","article-title":"Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial","volume":"7","author":"Di Stasi","year":"2006","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.ucl.2013.01.008_bib39","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S1470-2045(11)70190-5","article-title":"Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial","volume":"12","author":"Di Stasi","year":"2011","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.ucl.2013.01.008_bib40","first-page":"658","article-title":"A\u00a0randomized controlled study of intravesical alpha-2b-interferon in carcinoma in situ of the bladder","volume":"144","author":"Glashan","year":"1990","journal-title":"J\u00a0Urol"},{"issue":"6","key":"10.1016\/j.ucl.2013.01.008_bib41","first-page":"1793","article-title":"Superficial bladder cancer: the role of interferon-alpha","volume":"159","author":"Belldegrun","year":"1998","journal-title":"J\u00a0Urol"},{"issue":"4","key":"10.1016\/j.ucl.2013.01.008_bib42","first-page":"1300","article-title":"Salvage intravesical therapy with interferon-alpha 2b plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed","volume":"166","author":"O'Donnell","year":"2001","journal-title":"J\u00a0Urol"},{"issue":"4","key":"10.1016\/j.ucl.2013.01.008_bib43","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.urolonc.2005.11.026","article-title":"Final results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer","volume":"24","author":"Joudi","year":"2006","journal-title":"Urol Oncol"},{"issue":"3","key":"10.1016\/j.ucl.2013.01.008_bib44","first-page":"817","article-title":"Factors affecting response to bacillus Calmette-Guerin plus interferon for urothelial carcinoma in situ","volume":"186","author":"Rosevear","year":"2011","journal-title":"J\u00a0Urol"},{"issue":"1","key":"10.1016\/j.ucl.2013.01.008_bib45","first-page":"53","article-title":"Gemcitabine plus cisplatin for advanced transitional cell carcinoma of the urinary tract: a phase II multicenter trial","volume":"164","author":"Lorusso","year":"2000","journal-title":"J\u00a0Urol"},{"issue":"8","key":"10.1016\/j.ucl.2013.01.008_bib46","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0959-8049(98)00030-6","article-title":"A\u00a0phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer","volume":"34","author":"Lorusso","year":"1998","journal-title":"Eur J Cancer"},{"issue":"12","key":"10.1016\/j.ucl.2013.01.008_bib47","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.1997.15.12.3441","article-title":"Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer","volume":"15","author":"Moore","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.ucl.2013.01.008_bib48","doi-asserted-by":"crossref","first-page":"3394","DOI":"10.1200\/JCO.1997.15.11.3394","article-title":"Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer","volume":"15","author":"Stadler","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.ucl.2013.01.008_bib49","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1002\/cncr.23848","article-title":"A\u00a0role for neoadjuvant\u00a0gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience","volume":"113","author":"Dash","year":"2008","journal-title":"Cancer"},{"issue":"15","key":"10.1016\/j.ucl.2013.01.008_bib50","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1200\/JCO.2002.02.066","article-title":"Phase I trial of intravesical gemcitabine in bacillus Calmette-Guerin-refractory transitional-cell carcinoma of the bladder","volume":"20","author":"Dalbagni","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.ucl.2013.01.008_bib51","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1159\/000090870","article-title":"Intravesical gemcitabine in BCG-refractory T1G3 transitional cell carcinoma of the bladder: a pilot study","volume":"76","author":"Gacci","year":"2006","journal-title":"Urol Int"},{"issue":"4","key":"10.1016\/j.ucl.2013.01.008_bib52","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.urology.2005.04.062","article-title":"Intravesical gemcitabine therapy for superficial transitional cell carcinoma: results of a Phase II prospective multicenter study","volume":"66","author":"Bartoletti","year":"2005","journal-title":"Urology"},{"issue":"4","key":"10.1016\/j.ucl.2013.01.008_bib53","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1200\/JCO.2008.20.8199","article-title":"Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance","volume":"28","author":"Addeo","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"Suppl 4","key":"10.1016\/j.ucl.2013.01.008_bib54","first-page":"e673","article-title":"1666 SWOG S0353 phase II trial of intravesical gemcitabine in patients with non-muscle invasive bladder cancer who recurred following at least two prior courses of BCG","volume":"187","author":"Skinner","year":"2012","journal-title":"J\u00a0Urol"},{"issue":"3","key":"10.1016\/j.ucl.2013.01.008_bib55","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/S0090-4295(96)00621-8","article-title":"Initial report on intravesical administration of N-trifluoroacetyladriamycin-14-valerate (AD 32) to patients with refractory superficial transitional cell carcinoma of the urinary bladder","volume":"49","author":"Greenberg","year":"1997","journal-title":"Urology"},{"issue":"2","key":"10.1016\/j.ucl.2013.01.008_bib56","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S0090-4295(00)00654-3","article-title":"Pilot study of the tolerability and toxicity of intravesical valrubicin immediately after transurethral resection of superficial bladder cancer","volume":"56","author":"Patterson","year":"2000","journal-title":"Urology"},{"issue":"3","key":"10.1016\/j.ucl.2013.01.008_bib57","first-page":"761","article-title":"Efficacy and safety of valrubicin for the treatment of bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group","volume":"163","author":"Steinberg","year":"2000","journal-title":"J\u00a0Urol"},{"issue":"3","key":"10.1016\/j.ucl.2013.01.008_bib58","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s00345-002-0275-2","article-title":"New drugs and new approaches for the treatment of metastatic urothelial cancer","volume":"20","author":"Calabro","year":"2002","journal-title":"World J Urol"},{"issue":"6","key":"10.1016\/j.ucl.2013.01.008_bib59","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1007\/BF00686501","article-title":"Taxol and taxotere in bladder cancer: in\u00a0vitro activity and urine stability","volume":"33","author":"Rangel","year":"1994","journal-title":"Cancer Chemother Pharmacol"},{"issue":"19","key":"10.1016\/j.ucl.2013.01.008_bib60","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1200\/JCO.2005.03.1161","article-title":"Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical\u00a0therapy","volume":"24","author":"McKiernan","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.ucl.2013.01.008_bib61","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.urology.2009.06.112","article-title":"Long-term clinical outcomes of a phase I trial of intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to standard intravesical therapy","volume":"75","author":"Laudano","year":"2010","journal-title":"Urology"},{"issue":"11","key":"10.1016\/j.ucl.2013.01.008_bib62","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1158\/1078-0432.CCR-04-2291","article-title":"Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol)","volume":"11","author":"Sparreboom","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.ucl.2013.01.008_bib63","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1097\/CAD.0b013e32830f9046","article-title":"Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status","volume":"19","author":"Desai","year":"2008","journal-title":"Anticancer Drugs"},{"issue":"8","key":"10.1016\/j.ucl.2013.01.008_bib64","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1517\/14656566.7.8.1041","article-title":"Albumin-bound paclitaxel: a next-generation taxane","volume":"7","author":"Gradishar","year":"2006","journal-title":"Expert Opin Pharmacother"},{"issue":"31","key":"10.1016\/j.ucl.2013.01.008_bib65","doi-asserted-by":"crossref","first-page":"7794","DOI":"10.1200\/JCO.2005.04.937","article-title":"Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer","volume":"23","author":"Gradishar","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.ucl.2013.01.008_bib66","first-page":"448","article-title":"A\u00a0phase I trial of intravesical nanoparticle albumin-bound paclitaxel in the treatment of bacillus Calmette-Guerin refractory nonmuscle invasive bladder cancer","volume":"186","author":"McKiernan","year":"2011","journal-title":"J\u00a0Urol"},{"issue":"5\u20136","key":"10.1016\/j.ucl.2013.01.008_bib67","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.phrs.2008.09.008","article-title":"The in\u00a0vitro rabbit whole bladder as a model to investigate the urothelial transport of anticancer agents The ONCOFID-P paradigm","volume":"58","author":"Tringali","year":"2008","journal-title":"Pharmacol Res"},{"issue":"3","key":"10.1016\/j.ucl.2013.01.008_bib68","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.urolonc.2005.08.020","article-title":"HYTAD1-p20: a new paclitaxel-hyaluronic acid hydrosoluble bioconjugate for treatment of superficial bladder cancer","volume":"24","author":"Rosato","year":"2006","journal-title":"Urol Oncol"},{"issue":"2","key":"10.1016\/j.ucl.2013.01.008_bib69","first-page":"445","article-title":"Paclitaxel-hyaluronic acid for intravesical therapy of bacillus Calmette-Guerin refractory carcinoma in situ of the bladder: results of a phase I study","volume":"185","author":"Bassi","year":"2011","journal-title":"J\u00a0Urol"},{"issue":"1","key":"10.1016\/j.ucl.2013.01.008_bib70","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/jnci\/52.1.103","article-title":"Biologically active components from mycobacterial cell walls. II. Suppression and regression of strain-2 guinea pig hepatoma","volume":"52","author":"Meyer","year":"1974","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"5","key":"10.1016\/j.ucl.2013.01.008_bib71","first-page":"1633","article-title":"Mycobacterial cell wall extract for treatment of carcinoma in situ of the bladder","volume":"166","author":"Morales","year":"2001","journal-title":"J\u00a0Urol"},{"issue":"3","key":"10.1016\/j.ucl.2013.01.008_bib72","first-page":"1040","article-title":"Intravesical mycobacterial cell wall-DNA complex in the treatment of carcinoma in situ of the bladder after standard intravesical therapy has failed","volume":"181","author":"Morales","year":"2009","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.ucl.2013.01.008_bib73","unstructured":"Cohen Z. Efficacy and safety of mycobacterial cell wall DNA complex in the treatment of patients with non-muscle invasive bladder cancer at high risk of progression and who are refractory to BCG. Vienna (Austria): 26th annual EAU Congress 2011."},{"issue":"5","key":"10.1016\/j.ucl.2013.01.008_bib74","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.urolonc.2008.11.019","article-title":"Sequential intravesical gemcitabine and mitomycin C chemotherapy regimen in patients with non-muscle invasive bladder cancer","volume":"28","author":"Breyer","year":"2010","journal-title":"Urol Oncol"},{"issue":"4","key":"10.1016\/j.ucl.2013.01.008_bib75","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.urolonc.2010.06.012","article-title":"A\u00a0cocktail regimen of intravesical mitomycin-C, doxorubicin, and cisplatin (MDP) for non-muscle-invasive bladder cancer","volume":"30","author":"Chen","year":"2012","journal-title":"Urol Oncol"},{"issue":"6","key":"10.1016\/j.ucl.2013.01.008_bib76","first-page":"2391","article-title":"A\u00a0first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer","volume":"188","author":"Burke","year":"2012","journal-title":"J\u00a0Urol"},{"issue":"5","key":"10.1016\/j.ucl.2013.01.008_bib77","first-page":"1712","article-title":"A\u00a0phase II study of oportuzumab monatox: an immunotoxin therapy for patients with noninvasive urothelial carcinoma in situ previously treated with bacillus Calmette-Guerin","volume":"188","author":"Kowalski","year":"2012","journal-title":"J\u00a0Urol"},{"issue":"27","key":"10.1016\/j.ucl.2013.01.008_bib78","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1056\/NEJMoa041588","article-title":"A\u00a0multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer","volume":"351","author":"Paik","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.ucl.2013.01.008_bib79","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1093\/annonc\/mdl435","article-title":"Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy","volume":"18","author":"Bellmunt","year":"2007","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.ucl.2013.01.008_bib80","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1158\/0008-5472.CAN-09-3562","article-title":"The COXEN principle: translating signatures of in\u00a0vitro chemosensitivity into tools for clinical outcome prediction and drug discovery in cancer","volume":"70","author":"Smith","year":"2010","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.ucl.2013.01.008_bib81","first-page":"2094","article-title":"Predictive value of microtubule associated proteins tau and stathmin in patients with nonmuscle invasive bladder cancer receiving adjuvant intravesical taxane therapy","volume":"186","author":"Wosnitzer","year":"2011","journal-title":"J\u00a0Urol"}],"container-title":["Urologic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014313000098?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014313000098?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T13:24:24Z","timestamp":1758806664000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0094014313000098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":81,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["S0094014313000098"],"URL":"https:\/\/doi.org\/10.1016\/j.ucl.2013.01.008","relation":{},"ISSN":["0094-0143"],"issn-type":[{"type":"print","value":"0094-0143"}],"subject":[],"published":{"date-parts":[[2013,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New Agents for Bacillus Calmette-Gu\u00e9rin\u2013Refractory Bladder Cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ucl.2013.01.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}